Spectral AI, Inc. (MDAI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows mixed signals: improved net income and cash position are positive, but declining gross margins and R&D revenue are concerns. The Q&A section highlights strategic planning for commercialization but lacks specific details, which raises uncertainty. The absence of guidance adjustments and unclear management responses further contribute to a neutral sentiment. Overall, while there are positive elements, the uncertainties and lack of immediate catalysts keep the stock reaction neutral.
Key Financial Performance
Research and Development Revenue (Q4 2025) $3.8 million, compared to $7.6 million in Q4 2024, reflecting the anticipated reduction in research direct labor, clinical trial, and other reimbursed study costs as the company moved closer to completion of the base phase under the BARDA PBS contract.
Gross Margin (Q4 2025) 39.8%, compared to 44.0% in Q4 2024, due primarily to a lower percentage of reimbursed direct labor as a component of overall revenue from the BARDA PBS contract.
General and Administrative Expenses (Q4 2025) $4.0 million, down from $4.5 million in Q4 2024, reflecting lower spending on third-party accounting and legal providers.
Net Income (Q4 2025) $0.6 million, or $0.02 per diluted share, compared to a net loss of $7.7 million, or a negative $0.41 per diluted share in Q4 2024. The improvement was due to a $4 million gain in the fair value of the company's warrant liability as compared to a net loss of $5.4 million.
Research and Development Revenue (Full Year 2025) $19.7 million, down from $29.6 million in 2024, reflecting the anticipated overall reduction in the company's reimbursed costs associated with the BARDA PBS contract during 2025, following the company's submission of its de novo application to the FDA.
Gross Margin (Full Year 2025) 45.4%, compared to 44.9% in 2024, reflecting a consistent mix of direct labor as a percentage of the total work performed on the BARDA PBS contract from the prior year.
General and Administrative Expenses (Full Year 2025) $17.5 million, down from $19.9 million in 2024, reflecting a continued focus on operating efficiencies at the company.
Net Loss (Full Year 2025) $7.6 million, or a negative $0.29 per diluted share, compared to a net loss of $15.3 million, or a negative $0.85 per diluted share in 2024. The improvement was primarily due to the change in the fair value of the company's warrant liability, reduced borrowing-related costs of $1.5 million, net of amortization of debt discount, and improved operating efficiencies.
Cash Position (December 31, 2025) $15.4 million, up from $5.2 million on December 31, 2024, reflecting previously announced debt and equity financings completed during the year as well as warrant and stock option exercises.
Total Debt (December 31, 2025) $8.5 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DeepView System: The DeepView system is a diagnostic tool designed to assist medical personnel in determining whether a burn wound will heal on its own or requires medical intervention. It is particularly useful in mass casualty burn incidents. The system outperformed clinical judgment in a 15-month burn validation study involving 164 patients across 15 U.S. burn centers. The company submitted a de novo application to the FDA in June 2025 and is awaiting approval, expected by the end of Q2 2026. Post-approval, an outcome study will measure its real-world impact.
Handheld Device: The company is developing a handheld version of the DeepView system under a Department of Defense contract. A fully functioning prototype is expected by Q2 2026, with plans to seek FDA approval after the cart-based system is approved.
BARDA Contract: The company has a $150 million contract with BARDA, with $55 million awarded in 2023 and an additional $31.7 million awarded in 2025 to accelerate development. The contract includes subsidies for initial sales of up to 30 DeepView systems in U.S. burn centers and potentially 140 more systems in trauma centers and emergency departments.
International Expansion: The DeepView system has received UKCA authorization for burn indications in the U.K. Initial sales in the U.K., Australia, and Gulf Cooperation Council nations are anticipated to begin in late 2026, following expanded UKCA authorization.
Financial Position: The company ended 2025 with $15.4 million in cash, tripling its cash position from 2024. Operating expenses have been aligned with strategic priorities, and the company is in a strong liquidity position to pursue growth objectives.
Revenue and Efficiency: 2025 revenue from R&D decreased to $19.7 million from $29.6 million in 2024, reflecting reduced reimbursed costs under the BARDA contract. G&A expenses declined to $17.5 million from $19.9 million, indicating improved operational efficiencies.
Commercialization Strategy: The company plans to begin commercial activities for the DeepView system in 2026, leveraging existing manufacturing relationships and expanding its sales team. The strategy aims for rapid market adoption both domestically and internationally.
FDA Approval and Market Readiness: The company is actively engaging with the FDA for approval of the DeepView system. Approval is expected by Q2 2026, which will enable the company to transition to commercial sales and expand its market presence.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Delays: The company is awaiting FDA approval for its DeepView system, which is critical for commercialization. Any delays or negative feedback from the FDA could significantly impact the company's strategic plans and financial performance.
Dependence on BARDA Funding: The company heavily relies on funding from BARDA for product development and validation. Any reduction or withdrawal of this funding could disrupt ongoing projects and future advancements.
Commercialization Risks: The transition to commercial activities post-FDA approval involves uncertainties, including manufacturing scalability, sales team expansion, and market adoption challenges.
International Market Entry: Plans to expand into international markets like the UK, Australia, and Gulf Cooperation Council nations depend on regulatory approvals and market readiness, which could face delays or obstacles.
Financial Sustainability: While the company has improved its cash position, it remains dependent on external funding and successful commercialization to sustain operations and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA Approval Timeline: The company anticipates a positive response from the FDA regarding the DeepView system's de novo application by the end of the second quarter of 2026.
Outcome Study Post-FDA Approval: Following FDA clearance, the company plans to initiate an outcome study to measure the real-world impact of the DeepView system within hospital settings.
BARDA Contract Developments: BARDA awarded $31.7 million in advanced funding to accelerate the development of the DeepView system, with Spectral AI committing an additional $9.7 million. The contract includes provisions for subsidized initial sales and distribution of up to 30 DeepView systems upon FDA approval, with potential subsidies for an additional 140 systems.
International Expansion Plans: The company anticipates updating its UKCA authorization for the improved DeepView system in 2026, with initial sales in the U.K., Australia, or Gulf Cooperation Council nations expected to begin in late 2026.
Commercial Activities Timeline: Commercial activities for the DeepView system are expected to begin in earnest in 2026, leveraging existing manufacturing relationships and an expanded sales team.
Handheld Device Development: A fully functioning prototype of the handheld device is expected by the end of Q2 2026, with potential 510(k) approval following FDA approval of the cart-based DeepView system.
2026 Revenue Guidance: The company forecasts revenue of approximately $18.5 million for 2026, primarily driven by new BARDA funding, excluding significant contributions from DeepView system sales.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company preparing for commercialization and FDA approval?
A:The company is searching for a new Chief Commercial Officer, engaging Deloitte Consulting for strategic planning, and planning to expand the sales team. They aim to be ready for sales inside and outside of BARDA by late 2026.
Q:What is the expected commercial activity from the 30 systems distributed to burn centers?
A:Each health system will decide how to treat the device (purchase or lease). The company anticipates revenue from 3-year contracts for software licensing, device maintenance, and improvements. Significant revenue impact is expected in 2027 and 2028.
Q:How will the additional BARDA funding enhance the DeepView system?
A:The funding will support label expansion, improvements in TBSA offerings, enhanced EHR integration, better battery life, and user interface refinements. These upgrades aim to make the device more valuable in burn centers.
Q:How will the $31.7 million BARDA advance and remaining $63 million be utilized?
A:The funding will accelerate manufacturing, hospital system placements, economic outcome studies, and expanded label work. The contract runs through 2030, with significant activity expected by 2028.
Q:What is the timeline for BARDA funds disbursement and revenue guidance adjustments?
A:The BARDA contract extends to 2030, with acceleration through 2028. Revenue guidance adjustments depend on health systems' treatment of device deployment. Significant revenue is expected in 2027 and 2028, with international sales also contributing.
Q:How will the company optimize DeepView's value outside the U.S.?
A:The company plans to modify UKCA authorization to align with the FDA-reviewed DeepView system and deploy devices in the U.K., GCC, and Australia. Revenue models may differ based on nationalized health systems.
Q:What is the plan for training and implementation of DeepView systems?
A:The company will expand its sales and biomedical engineering teams to train health centers. The device is intuitive, and additional features are being developed to enhance user-friendliness. Device placements are expected in late 2026, with significant activity in 2027.
Q:What is the allocation of R&D spend for future developments?
A:R&D will focus on label expansion for head, hands, and feet, potential new indications like critical limb ischemia, and partnerships for wound bed preparedness. AI and ML advancements are also being considered.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of trainers required for device implementation and the exact timeline for placing the first units after FDA clearance. Additionally, they did not provide clarity on the breakdown of R&D spending for 2027 and beyond.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Full
Chief Executive
DeepView system
Equity Group
Executive Officer
Full Financial
PBS contract
Phase II
Research development
UKCA authorization
application FDA
approval FDA
burn center
cart DeepView
casualty
department United
device approval
emergency department
end review
history
hospital
loss share
novo application
patient
phase
position
product development
share loss
study DeepView
system burn
tool
trauma
user
validation study
MDAI Transcript
Spectral AI, Inc. (MDAI) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call summary shows mixed signals: improved net income and cash position are positive, but declining gross margins and R&D revenue are concerns. The Q&A section highlights strategic planning for commercialization but lacks specific details, which raises uncertainty. The absence of guidance adjustments and unclear management responses further contribute to a neutral sentiment. Overall, while there are positive elements, the uncertainties and lack of immediate catalysts keep the stock reaction neutral.
Spectral AI, Inc. (MDAI) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call highlights several negative factors: reduced revenue guidance, increased dependence on the BARDA contract, rising operating costs, and a net loss increase. Although there are some positive aspects, such as FDA submission progress and positive feedback from international markets, these are overshadowed by the negative financial trends and uncertainties about future revenue and commercialization. The Q&A session further underscores these concerns, with management providing vague responses on critical matters, contributing to a negative sentiment and likely negative stock price reaction.
Spectral AI, Inc. (MDAI) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals several concerning factors: a decreased gross margin, increased net loss, and heavy reliance on FDA approval and BARDA contract. The Q&A section indicates management's uncertainty regarding commercialization timelines and reliance on government contracts. Despite a reduction in G&A expenses, the financial strain from a significant net loss and limited revenue diversification suggests a negative outlook. The lack of immediate sales in international markets further compounds these issues. Consequently, the predicted stock price movement over the next two weeks is negative (-2% to -8%).
Spectral AI, Inc. (NASDAQ:MDAI) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call presents a mixed picture. Positive aspects include improved financial metrics, reduced losses, and a strong cash position. However, concerns arise from reliance on debt financing, competitive pressures, and vague responses in the Q&A about FDA deliverables and DoD contracts. The strong revenue growth and optimistic guidance are offset by uncertainties in operational changes and market competition, leading to a neutral sentiment prediction for stock price movement.
MDAI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
